>
Home > Trending on TAP > March 2019 > Alpha-Lipoic Acid and Inflammation: A Meta-Analysis

Alpha-Lipoic Acid and Inflammation: A Meta-Analysis

3/6/2019 4:13:10 PM
Chronic inflammation is associated with metabolic disorders. More specifically, increased levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor (TNF) are correlated with an increased risk for cardiovascular disease and diabetes. Alpha-lipoic acid (ALA) is an antioxidant nutrient that may reduce inflammation by scavenging free radicals or downregulating pro-inflammatory signaling cascades.
 
Clinical trials to evaluate the anti-inflammatory effects of ALA have produced mixed results. To summarize the currently available data on the effects of ALA on inflammatory markers in patients with metabolic disorders, researchers conducted a systematic review and meta-analysis.
 
Eighteen studies were included in the meta-analysis. All of the studies were placebo-controlled randomized trials involving adults with metabolic syndrome, cardiovascular disease, chronic kidney disease, diabetes, or related metabolic disorders. Studies reported on mean changes between pre- and post-intervention CRP, IL-6, or TNF-alpha following ALA supplementation.
 
The included studies ranged in duration from 2 weeks to 12 months. The dosage of oral ALA supplementation ranged from 300 mg to 600 mg per day. The results showed that ALA supplementation significantly decreased CRP by a standard mean difference (SMD) of -1.52 mg/L (95% CI, -2.25 to -0.80; p < .001). ALA decreased IL-6 by a mean of -1.96 pg/mL (95% CI, -2.60 to -1.32; p < .001) and decreased TNF-alpha by a mean of -2.62 pg/mL (95% CI, -3.70 to -1.55; p < .001).
 
There was significant heterogeneity among the studies, and the authors were not able to evaluate the effect of dosage or duration of ALA supplementation on inflammatory markers. More extensive studies are needed, but the current evidence suggests that ALA has a beneficial effect on inflammatory markers in patients with metabolic syndrome and other related disorders.
 
Reference
Akbari M, Ostadmohammadi V, Tabrizi R et al. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab (Lond). 2018; 15: 39.

Have Clinical Research Summaries Delivered to Your Inbox
TAP Integrative is your go-to resource for integrative clinical protocols, case studies, and evidence-based clinical information. Sign up for TAP’s enewsletter and receive integrative clinical research summaries, clinical pearls and tips from integrative experts delivered straight to your inbox. Bonus: Receive TAP’s top 3 patient education downloads FREE. Subscribe here >>>